Nitroprussiat Fides (Sodium Nitroprusside)

Sodium nitroprusside is a rapid‑acting vasodilator used in critical cardiovascular conditions.

• Hypertensive emergencies: provides immediate blood pressure reduction to prevent end‑organ damage.
• Acute heart failure: decreases preload and afterload, improving cardiac output and relieving pulmonary congestion.
• Controlled hypotension during surgery: maintains a target low arterial pressure to reduce bleeding and improve the surgical field.

• After intravenous administration, sodium nitroprusside releases nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. The resulting increase in cyclic guanosine monophosphate (cGMP) leads to relaxation of arterial and venous smooth muscle, producing a rapid fall in systemic vascular resistance and venous return, thereby lowering arterial pressure and reducing cardiac workload.

Sodium nitroprusside may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypotension: excessive drop in blood pressure, especially with rapid infusion.
• Reflex tachycardia: compensatory increase in heart rate.
• Headache: transient cranial discomfort.
• Nausea: mild gastrointestinal upset.
• Flushing: warm sensation and skin reddening.

Serious or Rare Side Effects

• Cyanide toxicity: accumulation leading to metabolic acidosis and neurologic signs.
• Methemoglobinemia: impaired oxygen delivery due to oxidized hemoglobin.
• Severe arrhythmias: including bradycardia or ventricular ectopy.

When using sodium nitroprusside, careful monitoring and specific precautions are essential to ensure patient safety.

• Blood pressure monitoring: continuous invasive measurement is required to adjust infusion rate.
• Infusion titration: adjust dosage based on real‑time hemodynamic response.
• Renal and hepatic function: assess before initiation, as impairment may increase risk of cyanide accumulation.
• Pregnancy considerations: use only if potential benefit justifies potential risk, as safety data are limited.
• Contraindications: avoid in patients with known cyanide metabolism disorders or severe anemia.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium nitroprusside can interact with several agents, influencing its hypotensive effect or increasing toxicity risk.

Major Interactions (Avoid)

• Other vasodilators (e.g., nitroglycerin, hydralazine): may cause profound hypotension.
• ACE inhibitors or ARBs: additive blood pressure lowering effect.
• MAO inhibitors: potential for severe hypotension.
• Beta‑blockers: may mask reflex tachycardia, complicating monitoring.

Moderate Interactions (Monitor Closely)

• Diuretics: enhance volume depletion and hypotensive response.
• Calcium channel blockers: additive vasodilatory effect.
• Digitalis glycosides: increased risk of arrhythmias when combined with rapid blood pressure changes.